3 February 2012 - Auxogyn Inc, a US company focused on women's reproductive health, said on Thursday it had closed the final tranche of its Series A financing, bringing the total funding to USD20m (EUR15.2m).

The initial tranche was placed in May 2010, and investors in the round include Kleiner Perkins Caufield and Byers, TPG Biotech and Merck Serono Ventures.

Over the course of the last year, the company has executed an aggressive operating plan in preparation for the commercialisation of its first product, Eeva, said Lissa Goldenstein, Auxogyn's president and CEO. Importantly, the firm expects to report data from its five-site, 150-patient clinical study in the months ahead that will then be used as part of the company's regulatory filings in Europe and the US, the chief executive added.

Auxogyn's first product, Early Embryo Viability Assessment (Eeva), provides quantitative information regarding embryo development, to assist IVF clinicians in optimising the treatment path for their patients undergoing IVF procedures.

(USD1 = EUR0.759)